Oana Petrenciuc

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela et al. · New England Journal of Medicine · 2020 · 360 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

Malcolm J. Moore, Holger W. Hirte, Lillian L. Siu et al. · Annals of Oncology · 2005 · 301 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

Fred Saad, Joan Carles, Silke Gillessen et al. · The Lancet Oncology · 2016 · 291 citations

Medicine, Oncology, Urology +17

Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma

Christine Elser, Lillian L. Siu, Eric Winquist et al. · Journal of Clinical Oncology · 2007 · 260 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

Lillian L. Siu, Ahmad Awada, Chris H. Takimoto et al. · Clinical Cancer Research · 2006 · 187 citations · Full text

Medicine, Oncology, Pharmacology +16